Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, [1] are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor.

2023年7月3日 · Healthcare providers prescribe GLP-1 agonists for two conditions: Type 2 diabetes and obesity. GLP-1 agonists for Type 2 diabetes. The FDA approves the use of GLP-1 agonists to help manage Type 2 diabetes (T2D). This is because GlP-1 …

2024年2月29日 · GLP-1 agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat T2DM and, in some cases, obesity. Examples of drugs in this class include Exenatide, Liraglutide, Dulaglutide, and Semaglutide.

2020年3月23日 · Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes. GLP-1 RAs are very effective at lowering blood sugar levels.

2024年9月18日 · We introduce recent studies that demonstrate the remarkable performance of GLP-1RAs in slowing the progression of neurodegenerative diseases, reducing inflammation, and enhancing cardiovascular...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while having a low risk of hypoglycemia. Some also have documented cardiovascular benefit.

2024年6月6日 · The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations.

2025年1月20日 · Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and risks have not yet been systematically evaluated in a comprehensive set of possible health outcomes.

2024年2月25日 · Glucagon-like peptide-1 agonists (GLP-1RA) are analogs of GLP-1, a gut-derived peptide hormone that exhibits a glucose-lowering effect via stimulation of insulin secretion from pancreatic islets in response to an oral glucose load, known as the incretin effect.

2024年10月7日 · GLP-1 receptor agonists are a non-insulin type 2 diabetes medication. GLP-1 agonists help to lower blood sugar and aid in weight loss. Drugs in this class include Byetta (exenatide), Victoza (liraglutide), Trulicity (dulaglutide), and Ozempic (semaglutide) among others.